Transfer RNA is among the most chemically decorated molecules in the cell — an average human tRNA carries more than a dozen distinct post-transcriptional modifications, each one placed with exquisite precision to fine-tune its performance on the ribosome. Among these, the family of 5-carboxymethyluridine (cm⁵U) modifications at the wobble position of the anticodon holds particular importance: present in more than half of wobble uridines in eukaryotic tRNAs, these chemical marks are indispensable for accurate codon-anticodon recognition during translation and, when absent or perturbed, have been linked to neurodegenerative disease. Yet despite considerable structural work on the enzyme responsible for installing them — the radical SAM enzyme Elp3, the catalytic core of the multiprotein Elongator complex — a fundamental mechanistic question had remained unresolved: how, precisely, does Elp3 execute this chemistry when its two essential active sites are separated by more than 20 angstroms?
A study published on 3 June 2026 in Nature Communications by Evan P. Geissler, Youmna Moawad, Paige N. Roehling, Katherine Martin, Papa Nii Asare-Okai, and Jeffrey S. Mugridge at the University of Delaware provides a compelling answer. Working with a model archaeal Elp3 enzyme that allows clean biochemical reconstitution of tRNA modification activity, the team combined structural analyses, enzymology, and isotope incorporation experiments to reveal that Elp3 harbours a conserved, enclosed molecular tunnel running through its interior, connecting the acetyl-CoA-binding lysine acetyltransferase (KAT) domain to the radical SAM (rSAM) active site where the actual chemistry of tRNA modification occurs. Remarkably, the authors found that free acetate — a simple two-carbon molecule — can be transported through this tunnel and substituted for the canonical cofactor acetyl-CoA to support radical-mediated carboxymethylation of the wobble uridine at position 34 of the tRNA anticodon. Isotope labelling experiments using ¹⁴C-acetate provided direct evidence for acetate incorporation into the tRNA product, confirming that the tunnel serves as an active conduit rather than a structural artefact.
The mechanistic picture that emerges challenges the previously assumed obligatory role of intact acetyl-CoA as the proximal acetyl donor and reframes the Elp3 reaction as a two-stage process in which intermediate transport through the enzyme tunnel is a key regulatory step. This tunnel, the authors demonstrate, is conserved across all three domains of life — an evolutionary signature pointing to deep functional significance. The work also provides the first documented example of acetate transport through an enzyme tunnel, extending a conceptual framework more familiar in the context of ammonia or carbon monoxide channeling to a chemically distinct and unexpected substrate.
The implications extend beyond enzymology. Elp3 and the Elongator complex are linked to a spectrum of human neurodegenerative diseases, including familial dysautonomia, amyotrophic lateral sclerosis, and various forms of intellectual disability, all associated with deficiencies in cm⁵U34-derived tRNA modification. Understanding the precise mechanism through which Elp3 installs this modification is therefore a prerequisite for rational drug development targeting this pathway. The newly described tunnel represents a structurally defined, evolutionarily conserved cavity that could in principle be exploited pharmacologically — either to inhibit Elp3 in contexts where its overactivation contributes to disease, or to develop activating strategies in loss-of-function settings. That said, important limitations temper immediate translational enthusiasm: the study relies on an archaeal model enzyme rather than the full human Elongator complex, and it remains unclear how the tunnel mechanism operates within the context of the larger Elp1-6 assembly, where additional subunits may modulate substrate access and cofactor dynamics in ways that remain to be resolved.
Taken together, this work resolves a long-standing structural paradox in tRNA biology and proposes a previously unrecognized mechanism for how an enzyme bridges distant active sites through the physical transport of small molecules. For a field in which tRNA modifications are increasingly recognized as both therapeutic targets and biomarkers of translational dysfunction, this represents a meaningful mechanistic advance.
Leave a Reply